20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- First Wave BioPharma Inc (NASDAQ:FWBI) has agreed with the former shareholders of First Wave Bio Inc to amend the payment structure of the initial merger consideration and extend payments into 2023.
- Related Link: AzurRx BioPharma To Acquire First Wave Bio For $229M.
- The amendment comes to provide the Company with additional financial resources for its ongoing Phase 2 trial programs.
- In September, the Company announced to acquire FWB for an upfront cash payment of $3 million and issued $4 million of common stock.
- The original remaining upfront consideration of $15 million has been restructured.
- Under the Revised Merger Agreement, the $15 million will be paid in smaller monthly installments from January 2022 through mid-year 2023 until satisfied.
- James Sapirstein, President and CEO of First Wave BioPharma, stated, "this revised agreement provides us with additional capital resources to advance our clinical programs through multiple value-enhancing milestones in 2022."
- Price Action: FWBI shares are down 6.04% at $2.17 during the market session on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!